tiprankstipranks
Advertisement
Advertisement
Cartesian Secures Major Loan Facility to Extend Runway
PremiumCompany AnnouncementsCartesian Secures Major Loan Facility to Extend Runway
20d ago
Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
Premium
The Fly
Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
1M ago
Cartesian Therapeutics management to meet with BTIG
Premium
The Fly
Cartesian Therapeutics management to meet with BTIG
2M ago
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe FlyCartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
3M ago
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
Premium
Ratings
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
3M ago
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
Premium
The Fly
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
3M ago
Cartesian Therapeutics announces employment inducement grants
PremiumThe FlyCartesian Therapeutics announces employment inducement grants
5M ago
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
Premium
Ratings
Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian Therapeutics
6M ago
Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
Premium
Ratings
Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100